Esperion Therapeutics, Inc. (ESPR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Esperion Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Esperion Therapeutics, Inc. (ESPR) has returned -25.95% so far this year and 90.28% over the past 12 months. Over the last ten years, ESPR has returned -16.92% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Jun 26, 2013, ESPR's average daily return is +0.09%, while the average monthly return is +1.93%. At this rate, your investment would double in approximately 3.0 years.

Historically, 53% of months were positive and 47% were negative. The best month was Dec 2023 with a return of +124.8%, while the worst month was Mar 2023 at -74.3%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 8 months.

On a daily basis, ESPR closed higher 50% of trading days. The best single day was Mar 20, 2017 with a return of +74.1%, while the worst single day was Mar 16, 2023 at -54.3%.

Esperion Therapeutics, Inc. has an annualized alpha of 6.90%, beta of 1.25, and R² of 0.07 versus S&P 500 Index. Calculated based on daily prices since June 27, 2013.

• This stock participated in 145.27% of S&P 500 Index downside but only 37.98% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.07 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ESPR ranks 72 for risk / return — better than 72% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Esperion Therapeutics, Inc. (ESPR) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Esperion Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Esperion Therapeutics, Inc. was 99.37%, occurring on May 14, 2025. The portfolio has not yet recovered.

The current Esperion Therapeutics, Inc. drawdown is 97.62%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Esperion Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Esperion Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.